Related Pages for DRREDDY
- Option Chain
- Straddle OC
- Max Pain
- Put Call Ratio
- Option Analytics
- Call OI vs Put OI
- Strike Flow
- Call OI Chg vs Put OI Chg
- Call Vol vs Put Vol
- Buildup & Unwinding
- Vega Divergence
- Multi Strike OI
- Multi Straddle Analysis
- Price vs OI
- Time Series Table
- Time Series Multi Chart
- Volatility Skew
- Premium Decay
- IV - HV
- IV Intraday
- Future Chain
- Future Intraday Analysis
- Technical
- Financials
- Chart
- About
No results found.
DRREDDY
Related News - DRREDDY
Dr. Reddy’s Laboratories: Plans Meeting With Analysts And Investors On September 25
21 Sep 2026 05:47 PM
Dr. Reddy’s Laboratories: Plans Meeting With Analysts And Investors On September 25
Dr. Reddy’s Labs: Takeda and Co. Team Up to Market Qdenga, India’s First Approved Dengue Vaccine for Kids and Adults.
18 Sep 2026 09:08 AM
Dr. Reddy’s Labs: Takeda and Co. Team Up to Market Qdenga, India’s First Approved Dengue Vaccine for Kids and Adults.
Dr Reddy's Labs:Co. Agrees To Licensing Deal With Gilead For Once-Yearly Lenacapavir To Prevent HIV.
18 Sep 2026 08:48 AM
Dr Reddy's Labs:Co. Agrees To Licensing Deal With Gilead For Once-Yearly Lenacapavir To Prevent HIV.
Dr Reddy's: Enters Royalty-Free License Agreement With Gilead For Annual Lenacapavir HIV Prevention.
17 Sep 2026 03:29 PM
Dr Reddy's: Enters Royalty-Free License Agreement With Gilead For Annual Lenacapavir HIV Prevention.
Dr. Reddy’s Labs: USFDA Finishes Inspection At Dr. Reddy’s Labs Facility In Morelos, Mexico Receives Two Observations In Form FDA 2953
12 Sep 2026 10:09 AM
Dr. Reddy’s Labs: USFDA Finishes Inspection At Dr. Reddy’s Labs Facility In Morelos, Mexico Receives Two Observations In Form FDA 2953
Drugmakers May Soon Need To Clearly Label Medicines As Synthetic Or Biological Under New Rules - Mint ( Biocon, Dr. Reddy, Zydus ) - Newspaper
02 Sep 2026 09:13 AM
Drugmakers May Soon Need To Clearly Label Medicines As Synthetic Or Biological Under New Rules - Mint ( Biocon, Dr. Reddy, Zydus ) - Newspaper
India Preps New Semaglutide Standards For Manufacturing & Testing As Rising Weight-loss Drug - Newspaper ( Dr Reddy’s, Biocon, Sun Pharma, Zydus Lifesciences & Lupin )
24 Aug 2026 09:13 AM
India Preps New Semaglutide Standards For Manufacturing & Testing As Rising Weight-loss Drug - Newspaper ( Dr Reddy’s, Biocon, Sun Pharma, Zydus Lifesciences & Lupin )
HC orders cancelling Razenta Pharma's Daplogin trademark on Dr Reddy's plea
20 Aug 2026 12:44 PM
HC orders cancelling Razenta Pharma's Daplogin trademark on Dr Reddy's plea
Dr. Reddy's: Launches First Generic Version Of Sugammadex Injection In The U.S.
04 Aug 2026 11:14 AM
Dr. Reddy's: Launches First Generic Version Of Sugammadex Injection In The U.S.
Dr. Reddy's Laboratories: Co Gets U.S. FDA Green Light For Rituximab Biosimilar; Fresenius Kabi To Exclusively Sell It In The U.S.; Approval Boosts Global Biosimilars Collection.
01 Aug 2026 11:38 AM
Dr. Reddy's Laboratories: Co Gets U.S. FDA Green Light For Rituximab Biosimilar; Fresenius Kabi To Exclusively Sell It In The U.S.; Approval Boosts Global Biosimilars Collection.
Dr. Reddy's: Expects Strong Performance In Q3 And Q4 After Fixing Semaglutide Problems.
30 Jul 2026 09:20 AM
Dr. Reddy's: Expects Strong Performance In Q3 And Q4 After Fixing Semaglutide Problems.
DR Reddy's: Receives Approval From Thai FDA For Nuzolvance (Zolifloxacin)
27 Jul 2026 02:40 PM
DR Reddy's: Receives Approval From Thai FDA For Nuzolvance (Zolifloxacin)
Dr Reddy's Laboratories: Guidance - Management maintains its guidance for EBITDA margin to be in the neighborhood of 20% for the next quarter, even without semaglutide, and expects higher margins with semaglutide resumption in November.- Comcall Update
23 Jul 2026 09:06 AM
Dr Reddy's Laboratories: Guidance - Management maintains its guidance for EBITDA margin to be in the neighborhood of 20% for the next quarter, even without semaglutide, and expects higher margins with semaglutide resumption in November.- Comcall Update
Dr Reddy's Laboratories: Guidance - The company plans to resume semaglutide commercial supplies by November, aiming to provide 6 million to 7 million pens between November and March, with high confidence in demand and partner relationships.- Comcall Update
23 Jul 2026 09:06 AM
Dr Reddy's Laboratories: Guidance - The company plans to resume semaglutide commercial supplies by November, aiming to provide 6 million to 7 million pens between November and March, with high confidence in demand and partner relationships.- Comcall Update
Dr Reddy's Laboratories: Guidance - R&D spend is guided to be in the range of 7% to 8% of revenues, with most investment directed towards products post-2034.- Comcall Update
23 Jul 2026 09:06 AM
Dr Reddy's Laboratories: Guidance - R&D spend is guided to be in the range of 7% to 8% of revenues, with most investment directed towards products post-2034.- Comcall Update
Dr Reddy's Laboratories: Guidance - The effective tax rate (ETR) is expected to be between 24% to 25% on a normalized basis for the full year.- Comcall Update
23 Jul 2026 09:07 AM
Dr Reddy's Laboratories: Guidance - The effective tax rate (ETR) is expected to be between 24% to 25% on a normalized basis for the full year.- Comcall Update
Dr Reddy's Laboratories: Guidance - CapEx cash outflow for the current year is projected to be around INR1,800 crore, down from the previous INR2,500-INR2,700 crore range, and is expected to stay at that level next year due to continuous investments in biosimilars and peptides.- Comcall Update
23 Jul 2026 09:07 AM
Dr Reddy's Laboratories: Guidance - CapEx cash outflow for the current year is projected to be around INR1,800 crore, down from the previous INR2,500-INR2,700 crore range, and is expected to stay at that level next year due to continuous investments in biosimilars and peptides.- Comcall Update
Dr Reddy's Laboratories: Guidance - The biologics business is expected to become profitable upon the launch of abatacept, with the goal date for US approval in mid-December 2026.- Comcall Update
23 Jul 2026 09:07 AM
Dr Reddy's Laboratories: Guidance - The biologics business is expected to become profitable upon the launch of abatacept, with the goal date for US approval in mid-December 2026.- Comcall Update
Dr Reddy's Laboratories: Guidance - The company is targeting 27 new product launches in the US for the rest of the year, with a specific launch in the next couple of weeks expected to generate tens of millions of dollars.- Comcall Update
23 Jul 2026 09:07 AM
Dr Reddy's Laboratories: Guidance - The company is targeting 27 new product launches in the US for the rest of the year, with a specific launch in the next couple of weeks expected to generate tens of millions of dollars.- Comcall Update
Dr. Reddy's: Citi on Dr. Reddy's Maintains Sell with Target Price ₹1,040 as margins fell to multi-year lows, weak US business and rising costs hurt profitability despite expected semaglutide supply recovery in 2HFY27.
23 Jul 2026 08:50 AM
Dr. Reddy's: Citi on Dr. Reddy's Maintains Sell with Target Price ₹1,040 as margins fell to multi-year lows, weak US business and rising costs hurt profitability despite expected semaglutide supply recovery in 2HFY27.
